Safety and short-term efficacy of neoadjuvant FLOT therapy in patients with resectable locally advanced esophageal squamous cell carcinoma

被引：0
|
作者：
Yoshinami, Y. [1 ]
Yamamoto, S. [1 ]
Shiraishi, K. [1 ]
Itoyama, M. [1 ]
Imazeki, H. [1 ]
Yokoyama, K. [1 ]
Honma, Y. [1 ]
Kurita, D. [2 ]
Ishiyama, K. [2 ]
Oguma, J. [2 ]
Daiko, H. [2 ]
Kato, K. [1 ]
机构：
[1] Natl Canc Ctr, Dept Head & Neck, Esophageal Med Oncol, Tokyo, Japan
[2] Natl Canc Ctr, Dept Esophageal Surg, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.329
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
415P
引用
收藏
页码：S168 / S168
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant versus adjuvant treatment: Which one is better for resectable locally advanced esophageal squamous cell carcinoma?
    Chen, Qixun
    Xu, Yaping
    Zheng, Yuanda
    Yu, Xinmin
    Lin, Qingren
    Jiang, Youhua
    Zhou, Xinming
    Mao, Weimin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] A Novel Predictor of Pathologic Complete Response for Neoadjuvant Immunochemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Yang, Yalan
    Xin, Dao
    Wang, Huike
    Guan, Lulu
    Meng, Xiangrui
    Lu, Taiying
    Bai, Xiwen
    Wang, Feng
    [J]. JOURNAL OF INFLAMMATION RESEARCH, 2023, 16 : 1443 - 1455
  • [33] Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
    Jun Yin
    Jingnan Yuan
    Yunjin Li
    Yong Fang
    Ruoxi Wang
    Heng Jiao
    Han Tang
    Shaoyuan Zhang
    Siyun Lin
    Feng Su
    Jianmin Gu
    Tian Jiang
    Dong Lin
    Zhiliang Huang
    Chaoxiang Du
    Kui Wu
    Lijie Tan
    Qing Zhou
    [J]. Nature Medicine, 2023, 29 : 2068 - 2078
  • [34] Comparison of efficacy and safety of neoadjuvant regimens for resectable esophageal squamous cell carcinoma: A meta-analysis
    Wang, Ting
    Cai, Liyu
    Guo, Zefeng
    You, Peimeng
    Liu, Shengbo
    Qiu, Hongrui
    Li, Hao
    Wu, Shaowei
    Zhou, Haiyu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
    Yin, Jun
    Yuan, Jingnan
    Li, Yunjin
    Fang, Yong
    Wang, Ruoxi
    Jiao, Heng
    Tang, Han
    Zhang, Shaoyuan
    Lin, Siyun
    Su, Feng
    Gu, Jianmin
    Jiang, Tian
    Lin, Dong
    Huang, Zhiliang
    Du, Chaoxiang
    Wu, Kui
    Tan, Lijie
    Zhou, Qing
    [J]. NATURE MEDICINE, 2023, 29 (08) : 2068 - +
  • [36] Use CT Imaging to Predict the Short-Term Outcome of Concurrent Chemoradiotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
    Cao, Xiaolan
    Li, Xindi
    Wang, Xiaoyue
    Duan, Jinghao
    Zhu, Shouhui
    Zeng, Haiyan
    Yin, Yong
    Yuan, Shuanghu
    Hu, Xudong
    [J]. DOSE-RESPONSE, 2019, 17 (04):
  • [37] Comparison of Open and Thoracoscopic Esophagectomy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy
    Hamai, Yoichi
    Emi, Manabu
    Ibuki, Yuta
    Kurokawa, Tomoaki
    Yoshikawa, Toru
    Hirohata, Ryosuke
    Ohsawa, Manato
    Kitasaki, Nao
    Okada, Morihito
    [J]. ANTICANCER RESEARCH, 2021, 41 (06) : 3011 - 3021
  • [38] Results of Neoadjuvant Chemoradiation Therapy Followed by Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma
    Murakami, Y.
    Nobuki, I.
    Doi, Y.
    Okabe, T.
    Kenjo, M.
    Kaneyasu, Y.
    Kimura, T.
    Hihara, J.
    Nagata, Y.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S337 - S337
  • [39] ORIGINAL RESE ARCH The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study
    Yin, Guo-Qiang
    Li, Zu-Lei
    Li, Dong
    [J]. CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2133 - 2141
  • [40] Neoadjuvant pembrolizumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim results.
    Wang, Weiwei
    Li, Li
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16011 - E16011
12345